NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases
Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes.
Colorectal Cancers Dial up Mutability in Response to Targeted Treatments
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
After Approval of Next-Gen Sequencing CDx Panel, Thermo Fisher Seeks Rapid Expansion of Indications
The initial FDA approval of Thermo Fisher's NGS panel test for personalizing cancer treatment may allow rapid expansion to new indications.